pharmaceutical investing NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”
U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia
Group Eleven Closes C$5.75M Bought Deal Private Placement, Including Full Exercise of C$750,000 Underwriters' Option